Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

Company Cites Continuing Progress on Clinical and Preclinical Programs

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, is pleased to provide an update covering its strategic and drug development activities for the second quarter of 2007.

"Callisto has made substantial progress with our clinical and preclinical programs in 2007," stated Gary S. Jacob, CEO of Callisto Pharmaceuticals. "In particular, the pace of our Phase II clinical trial of Atiprimod in neuroendocrine cancer patients continues to go well, and we expect to have full enrollment accomplished by the third quarter of 2007. "

The Atiprimod Phase II clinical trial in neuroendocrine carcinoma is a multiple-center, open-label study of the safety and efficacy of Atiprimod in low to intermediate grade neuroendocrine carcinoma patients. The trial, designed to enroll 40 patients, presently has 29 patients on study, and Callisto anticipates achieving the total enrollment of 40 patients in the third quarter of 2007. The trial was opened in November, 2006 and there are presently 5 clinical sites in the U.S. that are enrolling patients. The Company plans to have discussions with FDA some time in the fourth quarter of 2007 regarding the design of a pivotal trial in this disease indication.

Dr. Jacob continued, "We also have implemented a plan to develop Guanilib, Callisto's guanylyl cyclase C receptor agonist, to treat gastrointestinal disorders such as chronic constipation and irritable bowel syndrome. We plan to file an Investigational New Drug application with FDA in early 2008, and evaluate its potential initially in gastrointestinal disorders where there is a critical need for new drugs to treat the millions of patients currently suffering from these maladies."

About Guanilib

Guanilib (also called SP-304) is a potent analog (synt
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  Eiger BioPharmaceuticals, Incorporated today announced ... of lonafarnib in patients with chronic hepatitis delta viral ... program, enrolled at Ankara University Medical School, ... endemic. LOWR HDV - 1 (LOnafarnib ... study which randomized subjects to receive different doses of ...
(Date:4/27/2015)... 27, 2015 Kalorama Information expects the ... (EMR) to grow well past the period where ... to a recent report.  The healthcare market research ... continued efficiency improvements will grow the market seven ... five years.  The market for EMR systems continues ...
(Date:4/27/2015)... 2015  Novira Therapeutics, Inc., a privately held, clinical-stage ... chronic hepatitis B virus (HBV) infection, today announced the ... core inhibitor candidate, NVR 3-778, at the 2015 annual ... the Liver (EASL) in Vienna, Austria ... from studies performed in a humanized UPA/SCID mouse model ...
Breaking Medicine Technology:Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 2Eiger Bio Announces Interim Results of Lonafarnib in Combination with Ritonavir or Pegylated Interferon in Patients Infected with Hepatitis Delta Virus (HDV) 3Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 17, 2011 Damage to the spine can happen for ... car accident, wear and tear from old age, or blunt ... past have had to deal with back braces, reduced mobility, ... Seyed M. Rezaian,s patented Spinal Fixator, patients are able to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... Deputy Secretary of the U.S. Department of Agriculture, for a ... at its facility in York, Pennsylvania. The White ... direction of President Obama. The Winning the Future Roundtables ...
Cached Medicine Technology:Dr. Seyed M. Rezaian's Spinal Fixator a Revolutionary Invention for Healing Injuries of the Thoracolumbar Spine 2Unilife Hosts White House Business Council Meeting 2Unilife Hosts White House Business Council Meeting 3
(Date:4/27/2015)... 27, 2015 Women may have a ... according to a new study published online in the ... brain injury (MTBI), is a common medical problem affecting ... , In most cases, patients who experience MTBI ... 15 percent of MTBI patients will continue to experience ...
(Date:4/27/2015)... Moreno Ranches, a producer of Brahman ... to announce their "This is It" educational Brahman cattle ... breeding and education was a huge success. The educational ... 2015. It brought together youth, educators, and experts ... breeding in general, and Brahman cattle breeding in particular. ...
(Date:4/27/2015)... April 27, 2015 UC Davis ... molecular basis of an inherited disorder that historically ... also arises in other populations of Semitic descent, ... series of elegant experiments, the researchers uncovered the ... leukodystrophy that is an incurable and progressively fatal ...
(Date:4/27/2015)... April 27, 2015 On May 5, people ... ask their social media friends around the world to join ... asthma. , May 5 is World Pulmonary Hypertension Day ... leader in the global PH community, will take part in ... blood pressure of the lungs. PH is an increase in ...
(Date:4/27/2015)... Array Health , a leading provider ... Lance Hood, senior director of marketing, will participate in ... Health Care Marketing Summit on April 29, 2015. ... Director of Payer Services, Leavitt Partners, LLC, will address ... a retail/e-commerce perspective – and equip attendees with the ...
Breaking Medicine News(10 mins):Health News:Women Show Persistent Memory Impairment after Concussion 2Health News:Women Show Persistent Memory Impairment after Concussion 3Health News:Leading Ranch for Brahman Cattle for Sale, Moreno Ranches, Announces Conclusion of 'This is It' Event for Brahman Juniors. 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 2Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 3Health News:UC Davis Makes Breakthrough in Understanding Canavan Disease 4Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 2Health News:Pulmonary Hypertension Association Marks World PH Day on May 5 with a Worldwide Lifesaving Social Media Blitz 3Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2
... life when some students pushed him from the front bench in ... ,Qamar Irfan, a Class 5 student of Sarda Convent School in ... forcibly pushed off the bench by students in a fight over ... members, Qamar rushed into the class as soon as school opened ...
... diagnosed with stomach cancer. He was 68 years old then.// ... out that the hospital pathologist had misdiagnosed tests and Mr. ... out in October 2002 at Walsall Manor Hospital. The pathologist ... Wolverhampton trust. Royal Wolverhampton Hospitals NHS Trust owned up liability ...
... who are circumcised are less likely to contract HIV ... research presented recently at the International AIDS Conference at ... percent less likely to contract HIV than their uncircumcised ... ,Circumcision is the surgical removal of the foreskin ...
... New York shows that patients, who experience the health ... //be a lot done for its improvement, with almost ... health care. ,According to the ... Performance Health System, an astonishingly high amount of Americans, ...
... According to a new study by Duke University Medical ... the rate of treatment //for chronic hepatitis C than ... in the August issue of Gastroenterology, which is the ... (AGA), that the African American patients with hepatitis C ...
... The Health Service Executive in Ireland is all set to ... emergency overcrowding.// ,The Irish Examiner reports that hospitals may ... with the A&E crisis, where patients are made to wait ... A&E patients are not made to wait over 24 hours. ...
Cached Medicine News:Health News:Majority Of People In US Seek Essential Changes In Health Care System 2Health News:Majority Of People In US Seek Essential Changes In Health Care System 3Health News:Majority Of People In US Seek Essential Changes In Health Care System 4Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 2Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 3
IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
... RSV Test utilizes a new, improved format that ... rapid RSV detection. The testing device employs innovative ... reagents have already been applied to the testing ... with clear-cut results shown by the appearance of ...
Latex agglutination slide test for the qualitative detection of rotavirus from fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: